You are here

Our science / Clinical Trials / Find a Trial / NCT02122146

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Back to Search Print Save as PDF Bookmark Trial

NCT02122146

Last updated on March 22, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Keck Hospital of USC
Los Angeles, California, 90033 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
or for whom no standard therapy is available

- Performance Status of 0 or 1

- Adequate bone marrow, kidney and liver function

- Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Brain metastases requiring steroids

- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start (6 weeks for mitomycin C or nitrosoureas)

- Active and clinically significant bacterial, fungal, or viral infection

NCT02122146
Pfizer
Terminated
A Study Of PF-06664178 In Patients With Advanced Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Breast Neoplasms
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
NCT01176916
Females
0+
Years
Multiple Sites
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
NCT01945775
All Genders
18+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
PF-06804103 Dose Escalation in HER2 Positive Solid Tumors
NCT03284723
All Genders
18+
Years
Multiple Sites
Neoplasms
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
NCT02659631
All Genders
18+
Years
Multiple Sites
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Neoplasms
  • Drug: PF-06664178
    Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
  • Drug: PF-06664178
    Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
Experimental: PF-06664178
Experimental
Interventions:
  • Drug: PF-06664178
  • Drug: PF-06664178
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
31
June 2016
June 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
  • Performance Status of 0 or 1
  • Adequate bone marrow, kidney and liver function
  • Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Exclusion Criteria:

  • Brain metastases requiring steroids
  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
  • Active and clinically significant bacterial, fungal, or viral infection
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02122146
B7401001
2015-002704-84 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now